Literature DB >> 222445

Relationship between the intracellular cyclic adenosine 3':5'-monophosphate level of tumor cells and their sensitivity to killing by antibody and complement.

T N Lo, M D Boyle.   

Abstract

Metabolic inhibitors which have been shown to increase the sensitivity of the guinea pig hepatoma, line 10, to antibody-guinea pig complement killing were tested for their effect on the intracellular cyclic adenosine 3':5'-monophosphate (cAMP) level of the line 10 cells. It was found that cells rendered sensitive to antibody-guinea pig complement killing following drug treatment showed a decrease in their intracellular cAMP levels. Increased susceptibility to lysis was always associated with decreased intracellular cAMP levels. Optimal doses of certain inhibitors effectively increased the sensitivity of the cells to complement-dependent lysis and decreased the intracellular cAMP levels. Other drugs which did not increase sensitivity of the cells to lysis also failed to decrease the intracellular cAMP levels. No experimental conditions were found in which intracellular cAMP levels were decreased without an increase in the susceptibility of the cells to antibody-guinea pig complement killing.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 222445

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  4 in total

Review 1.  Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects.

Authors:  B P Morgan
Journal:  Biochem J       Date:  1989-11-15       Impact factor: 3.857

2.  Adriamycin inhibits PTH-mediated but not PGE2-mediated stimulation of cyclic AMP formation in isolated bone cells.

Authors:  G Kohler; V Shen; W A Peck
Journal:  Calcif Tissue Int       Date:  1984-05       Impact factor: 4.333

3.  Complement Membrane Attack and Tumorigenesis: A SYSTEMS BIOLOGY APPROACH.

Authors:  Laurence D Towner; Richard A Wheat; Timothy R Hughes; B Paul Morgan
Journal:  J Biol Chem       Date:  2016-05-19       Impact factor: 5.157

4.  Rationale, design, and methodology of a trial evaluating three models of care for HCV treatment among injection drug users on opioid agonist therapy.

Authors:  Matthew J Akiyama; Linda Agyemang; Julia H Arnsten; Moonseong Heo; Brianna L Norton; Bruce R Schackman; Benjamin P Linas; Alain H Litwin
Journal:  BMC Infect Dis       Date:  2018-02-09       Impact factor: 3.667

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.